Leveraging GLP-1 Receptor Agonist Options to Advance Glycemic Goals in Type 2 Diabetes
  • CME
  • CE

Learn about the appropriate use of GLP-1 RAs to address elevated A1C, obesity, and CV risk, as well as strategies to improve tolerability and adherence.
John J. Russell, MD
Neil Skolnik, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Nurse Practitioners: 1.0 AANP contact hour
Released: July 13, 2020 Expiration: July 12, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Examine the evidence that supports the use of GLP-1 RA products in patients with T2D regarding their impact on weight and CV risk
  • Summarize the latest findings on renal outcomes from recent studies of GLP-1 RA products and implications for drug selection in patients at increased risk for nephropathy due to T2D
  • Differentiate the pharmacokinetic and pharmacodynamic characteristics of long-acting injection and emerging oral GLP-1 RA products and how to optimize their use early in the T2D disease course
  • Explore strategies to help patients prevent or overcome gastrointestinal adverse events and to improve rates of adherence with GLP-1 RA therapy

Information on this Educational Activity

Faculty

John J. Russell, MD

Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Philadelphia, Pennsylvania
Chair, Department of Family and Community Medicine
Abington-Jefferson Health
Abington, Pennsylvania

John Russell, MD, has disclosed the following financial relationships: Consultant: Sanofi Pasteur, GlaxoSmithKline Speaker: Sanofi Pasteur
Neil Skolnik, MD

Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, Pennsylvania
Associate Director
Family Medicine Residency Program
Abington Jefferson Health
Abington, Pennsylvania

Neil Skolnik, MD, has disclosed the following financial relationships: Advisory Board Member: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, GlaxoSmithKline, Intarcia Therapeutics, Inc., Janssen, Merck & Co., Inc., Mylan, Sanofi Pasteur, and Teva Research: AstraZeneca, Boehringer Ingelheim, and Sanofi Speaker: AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, and GlaxoSmithKline

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.

Target Audience

Primary Care Providers

Physician Continuing Medical Education

Accreditation Statement

The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NACE AANP Approval

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0  contact hour of continuing education which includes 0.75 pharmacology hours.

Program Medium

This program has been made available online.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?